Promacta contains the active ingredient eltrombopag, an oral thrombopoietin receptor agonist (TPO-RA) used to treat specific conditions associated with low platelet counts. It is indicated for patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other therapies, as well as for certain patients with severe aplastic anemia and thrombocytopenia related to chronic hepatitis C infection.

Eltrombopag works by binding to and activating the thrombopoietin (TPO) receptor on bone marrow cells, stimulating the production of platelets. Increased platelet levels can help reduce the risk of bleeding and improve disease management in patients with chronic platelet deficiencies.

Promacta is available as oral tablets and oral suspension formulations in various strengths. Treatment is individualized based on platelet response and patient characteristics, with regular monitoring required to maintain platelet counts within a safe target range. The medication should be taken according to specific dietary instructions, as certain minerals and foods can affect absorption.

Clinical studies have demonstrated that Promacta can significantly increase platelet counts and reduce bleeding episodes in eligible patients. In severe aplastic anemia, it may also help improve other blood cell counts when used as part of an appropriate treatment regimen.

Common side effects may include nausea, headache, fatigue, diarrhea, upper respiratory tract infections, and elevated liver enzymes. Serious risks include liver toxicity, blood clots, bone marrow changes, and cataracts. Patients should undergo regular blood tests and liver function monitoring during treatment.